HAIFA, Israel, October 19 /PRNewswire/ -- To ensure that more women have
access to and learn about non-invasive treatment options for symptomatic
uterine fibroids, InSightec has launched an educational program on its
ExAblate(R) 2000 procedure for obstetrician/gynecologists (OB/GYNs), the
company said today. The ExAblate(R) 2000 will be highlighted at two OB/GYN
medical conferences this fall: the meeting of the 61st Annual meeting of the
American Society for Reproductive Medicine (ASRM) held conjointly with the
Canadian Fertility and Andrology Society, October 15-19 in Montreal; as well
as the Global Congress of Minimally Invasive Gynecology at the American
Association of Gynecologic Laparoscopists (AAGL) 34th Annual Meeting in
Chicago, November 9 -12.
The ExAblate 2000 combines magnetic resonance imaging (MRI) with
highly-focused ultrasound to destroy tumors non-invasively in the body.
ExAblate 2000 is the first U.S. Food and Drug Administration-approved system
to use the breakthrough MR-guided focused ultrasound technology that combines
MRI to visualize the uterus and high intensity focused ultrasound to
thermally ablate or destroy harmful tissue.
To date, approximately 1,200 women have been treated with ExAblate 2000
for uterine fibroids, a benign condition that affects approximately 25
percent of women. Clinical trials are underway for bone, liver, and breast
At ASRM on Saturday, Oct. 15, Elizabeth A. Stewart, M.D., Clinical
Director of the Center for Uterine Fibroids at Brigham and Women's Hospital
and Associate Professor of Obstetrics, Gynecology and Reproductive Biology at
Harvard Medical School, discussed research on this modality of treatment for
uterine fibroids as a part of her presentation of Innovative Therapies in the
session entitled "Modern Approaches to Uterine Fibroids."
"As the body of clinical data continues to grow in support of minimally-
and non-invasive techniques for uterine fibroids, more OB/GYNs are
recognizing the value this new MR-guided focused ultrasound technology holds
for treating women with symptomatic uterine fibroids," said Dr. Stewart.
"Women who may not have previously undergone uterine fibroid therapy because
of the hospital stays, risks and side effects involved with traditional
treatments now have the option to threat their condition in the outpatient
setting without surgery."
At ASRM, InSightec exhibited the ExAblate 2000 in the GE Healthcare
booths (#113 and #117). In August, InSightec signed a global sales and
marketing agreement with GE Healthcare for the sales and marketing of its
ExAblate(R) 2000. The ExAblate 2000 works exclusively with the Signa MR
systems made by GE Healthcare.
At AAGL, InSightec will exhibit the ExAblate 2000 at booth #718. In
addition, the ExAblate 2000 will be discussed during a postgraduate course on
excisional and non-excisional management of uterine leiomyomas during the
conference on Wednesday, Nov. 9th.
InSightec Image Guided Treatment Ltd. is a privately held company owned
by Elbit Medical Imaging (EMI), General Electric, private investors and
employees. It was founded in 1999 to develop the breakthrough MR guided
Focused Ultrasound technology and transform it into the next generation
operating room. Headquartered near Haifa, Israel, the company has over 100
employees and has invested more than $80 million in research, development,
and clinical investigations. Its U.S. headquarters are located in Dallas,
Texas. For more information, please go to: http://www.insightec.com/
For media inquiries, contact:
Lazar Partners, Ltd.
For more information about uterine fibroids, please visit
SOURCE InSightec Ltd.